OncoTherapy Science, Inc. (FRA:30O)
0.0965
+0.0110 (12.87%)
At close: Nov 28, 2025
OncoTherapy Science Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 1,675 | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade |
Cash & Short-Term Investments | 1,675 | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade |
Cash Growth | 52.55% | 58.06% | -52.82% | -39.16% | -36.67% | -38.49% | Upgrade |
Accounts Receivable | 44 | 98 | 35 | 123 | 399 | 152 | Upgrade |
Other Receivables | - | - | 153 | - | - | - | Upgrade |
Receivables | 44 | 98 | 188 | 123 | 399 | 152 | Upgrade |
Inventory | 91 | 78 | 73 | 99 | 231 | 41 | Upgrade |
Other Current Assets | 75 | 96 | 29 | 83 | 134 | 102 | Upgrade |
Total Current Assets | 1,885 | 1,105 | 817 | 1,422 | 2,600 | 3,194 | Upgrade |
Property, Plant & Equipment | - | - | - | - | - | 94 | Upgrade |
Long-Term Investments | 49 | 49 | 49 | 89 | 84 | 74 | Upgrade |
Other Intangible Assets | - | - | - | - | - | 4 | Upgrade |
Other Long-Term Assets | 1 | 1 | 1 | - | 1 | 2 | Upgrade |
Total Assets | 1,935 | 1,155 | 867 | 1,511 | 2,685 | 3,368 | Upgrade |
Current Income Taxes Payable | 204 | 163 | 141 | 318 | 558 | 174 | Upgrade |
Other Current Liabilities | 14 | 164 | 218 | 291 | 46 | 20 | Upgrade |
Total Current Liabilities | 218 | 327 | 359 | 609 | 604 | 194 | Upgrade |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 2 | Upgrade |
Other Long-Term Liabilities | 72 | 100 | 155 | 48 | 102 | 97 | Upgrade |
Total Liabilities | 290 | 427 | 514 | 657 | 706 | 293 | Upgrade |
Common Stock | 786 | 50 | 50 | 789 | 789 | 50 | Upgrade |
Additional Paid-In Capital | 28,252 | 27,516 | 26,322 | 24,793 | 24,793 | 24,054 | Upgrade |
Retained Earnings | -27,463 | -26,908 | -26,092 | -24,804 | -23,686 | -21,114 | Upgrade |
Comprehensive Income & Other | 70 | 70 | 73 | 76 | 83 | 85 | Upgrade |
Total Common Equity | 1,645 | 728 | 353 | 854 | 1,979 | 3,075 | Upgrade |
Shareholders' Equity | 1,645 | 728 | 353 | 854 | 1,979 | 3,075 | Upgrade |
Total Liabilities & Equity | 1,935 | 1,155 | 867 | 1,511 | 2,685 | 3,368 | Upgrade |
Net Cash (Debt) | 1,675 | 833 | 527 | 1,117 | 1,836 | 2,899 | Upgrade |
Net Cash Growth | 52.55% | 58.06% | -52.82% | -39.16% | -36.67% | -38.49% | Upgrade |
Net Cash Per Share | 5.92 | 3.19 | 2.48 | 5.80 | 9.79 | 16.44 | Upgrade |
Filing Date Shares Outstanding | 338.64 | 277.64 | 239.34 | 206.64 | 192.64 | 176.33 | Upgrade |
Total Common Shares Outstanding | 338.64 | 271.64 | 217.64 | 192.64 | 192.64 | 176.33 | Upgrade |
Working Capital | 1,667 | 778 | 458 | 813 | 1,996 | 3,000 | Upgrade |
Book Value Per Share | 4.86 | 2.68 | 1.62 | 4.43 | 10.27 | 17.44 | Upgrade |
Tangible Book Value | 1,645 | 728 | 353 | 854 | 1,979 | 3,071 | Upgrade |
Tangible Book Value Per Share | 4.86 | 2.68 | 1.62 | 4.43 | 10.27 | 17.42 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.